TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35852274

Group type: EXPERIMENTAL
Intervention: 20-mL buffered 1% lidocaine paracervical block
Number of subjects: 114

Group type: COMPARATOR
Intervention: 40-mL buffered 0.5% lidocaine paracervical block
Number of subjects: 114

Group type: COMPARATOR
Intervention: 40-mL buffered 0.5% lidocaine paracervical block (induced abortion)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 20-mL buffered 1% lidocaine paracervical block (induced abortion)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 20-mL buffered 1% lidocaine paracervical block (pain during administration)
Number of subjects: 114

Group type: COMPARATOR
Intervention: 40-mL buffered 0.5% lidocaine paracervical block (pain during administration)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both groups (side effects)
Number of subjects: 114
Study: 34859526

Group type: EXPERIMENTAL
Intervention: e-cigarettes offered by clinicians as a harm reduction strategy
Number of subjects: 21
Study: 33974054

Group type: EXPERIMENTAL
Intervention: BPD diagnosis
Number of subjects: 36309

Group type: EXPERIMENTAL
Intervention: BPD diagnosis with 5 criteria
Number of subjects: 36309

Group type: EXPERIMENTAL
Intervention: BPD diagnosis excluding self-injurious behavior
Number of subjects: 36309

Group type: EXPERIMENTAL
Intervention: Self-injurious behaviors
Number of subjects: 36309

Group type: EXPERIMENTAL
Intervention: Chronic feelings of emptiness
Number of subjects: 36309
Study: 32701901

Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36339149

Group type: EXPERIMENTAL
Intervention: HUA risk model
Number of subjects: 610
Study: 33308998

Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33140287

Group type: EXPERIMENTAL
Intervention: Engagement (self-reports)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Program-analytic indicator of dosage
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Observational indicator
Number of subjects: 310
Study: 35803368

Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion (TCI) of propofol (effect-site, 2 μg.mL−1 plus 0.5 μg.mL−1 until unconsciousness and as necessary for agitation)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intermittent bolus of propofol (1 mg.kg−1 plus 0.5 mg.kg−1 every 5 minutes or as necessary)
Number of subjects: 50
Study: 34656105

Group type: EXPERIMENTAL
Intervention: Male caregivers
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Working caregivers
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Female working caregivers
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Male working caregivers
Number of subjects: 1038
Study: 32480103

Group type: EXPERIMENTAL
Intervention: Kinship Navigator Programs (Kinship Navigator Peer to Peer and Kinship Navigator with Innovations)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual Child Welfare
Number of subjects: 240
Study: 35802637

Group type: EXPERIMENTAL
Intervention: Guided mobile-based perinatal mindfulness intervention (GMBPMI)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Psychoeducation (Control)
Number of subjects: 198
Study: 34626060

Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen 5 mg/day (babytam)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 32539675

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 321501

Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 321501

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 321501

Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 321501
Study: 35805699

Group type: EXPERIMENTAL
Intervention: Wuqinxi Qigong (WQ)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study: 33724534

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: High baseline sGFAP concentrations (≥170 pg/ml)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Attack severity
Number of subjects: 215
Study: 33884442

Group type: EXPERIMENTAL
Intervention: Synthetic medial meniscus replacement (MMR)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Non-surgical care
Number of subjects: 127
Study: 32900329

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg 12-hourly
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 48
Study: 35657627

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 114

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 114
Study: 36462539

Group type: EXPERIMENTAL
Intervention: Vaginal cleansing with 1% povidone-iodine
Number of subjects: 608

Group type: COMPARATOR
Intervention: Abdominal cleansing alone (Control)
Number of subjects: 608
Study: 34160182

Group type: EXPERIMENTAL
Intervention: UHC plus a 30-day NP transitional care intervention
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: UHC plus NP plus 60-day health coach intervention
Number of subjects: 495

Group type: COMPARATOR
Intervention: Usual home care (UHC)
Number of subjects: 495
Study: 32331049

Group type: EXPERIMENTAL
Intervention: 1800 mg SPN-812 (supratherapeutic dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 400 mg moxifloxacin (positive control)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 35000914

Group type: EXPERIMENTAL
Intervention: HEP+PWHi (High Intensity Ultrasound, 10% hydrocortisone gel, 10 minutes, 1.0 MHz, 50% duty cycle, 1.0 W/cm2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HEP+CWHi (Constant Ultrasound, 10% hydrocortisone gel, 10 minutes, 1.0 MHz, 100% duty cycle, 1.0 W/cm2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HEP+PWLi (Low Intensity Ultrasound, 10% hydrocortisone gel, 10 minutes, 1.0 MHz, 50% duty cycle, 0.5 W/cm2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HEP+CWLi (Low Intensity Ultrasound, 10% hydrocortisone gel, 10 minutes, 1.0 MHz, 100% duty cycle, 0.5 W/cm2)
Number of subjects: 25

Group type: COMPARATOR
Intervention: HEP (Home Exercise Program, 5 times a week)
Number of subjects: 25
Study: 32522156

Group type: EXPERIMENTAL
Intervention: LOR with epidural electrical stimulation (group E)
Number of subjects: 54

Group type: COMPARATOR
Intervention: LOR (group L)
Number of subjects: 54
Study: 36117007

Group type: EXPERIMENTAL
Intervention: Arthrocentesis as initial treatment
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-surgical intervention
Number of subjects: 84
Study: 33632925

Group type: EXPERIMENTAL
Intervention: Nivolumab with ipilimumab and two cycles of platinum-doublet chemotherapy
Number of subjects: 719
Study: 33258357

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 100
Study: 34351285

Group type: EXPERIMENTAL
Intervention: Information feedback with social comparison reference points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information feedback with social comparison reference points (proximate norm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 0
Study: 32223044

Group type: EXPERIMENTAL
Intervention: High dose EPC (140 mg EPC and 130 mg OPC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OPC (6 mg EPC and 130 mg OPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose EPC (70 mg EPC and 65 mg OPC)
Number of subjects: 0
Study: 32096616

Group type: EXPERIMENTAL
Intervention: Robotic Arm Training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional Arm Training
Number of subjects: 20
Study: 35679115

Group type: EXPERIMENTAL
Intervention: Telephone remote delivery method for health coaching
Number of subjects: 300

Group type: COMPARATOR
Intervention: Videoconference remote delivery method for health coaching
Number of subjects: 300
Study: 35848575

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TS)
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 1499

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1499
Study: 34341379

Group type: EXPERIMENTAL
Intervention: High protein supplementation (Investigational Product, IP)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Isocaloric normoproteic comparator (CP)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: High protein supplementation (IP)
Number of subjects: 107
Study: 32012064

Group type: EXPERIMENTAL
Intervention: Web-based, computer-tailored intervention (Alerta Alcohol)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Control condition (baseline questionnaire only)
Number of subjects: 612
Study: 33285097

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab plus platinum–etoposide
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: Durvalumab plus platinum–etoposide
Number of subjects: 805

Group type: COMPARATOR
Intervention: Platinum–etoposide
Number of subjects: 805
Study: 32763628

Group type: EXPERIMENTAL
Intervention: EEG activity during the composition task
Number of subjects: 0

Group type: COMPARATOR
Intervention: EEG activity during the list task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-word composition task
Number of subjects: 0
Study: 36343845

Group type: EXPERIMENTAL
Intervention: Hybrid endoscopic submucosal dissection (H-ESD)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Conventional endoscopic submucosal dissection (C-ESD)
Number of subjects: 79
Study: 33740892

Group type: EXPERIMENTAL
Intervention: Itopride
Number of subjects: 76

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 76
Study: 32950416

Group type: EXPERIMENTAL
Intervention: Litos drug-coated balloon (DCB)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Number of subjects: 105
Study: 34263700

Group type: EXPERIMENTAL
Intervention: Infliximab added to DMARD combination
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo added to DMARD combination
Number of subjects: 99
Study: 33858020

Group type: EXPERIMENTAL
Intervention: Motivational‐volitional program (MoVo‐BnB) with 4 sessions led by physiotherapeutic and health pedagogic personnel
Number of subjects: 545

Group type: COMPARATOR
Intervention: Standard rehabilitation (Control Group)
Number of subjects: 545
Study: 33469270

Group type: EXPERIMENTAL
Intervention: Generic obeticholic acid (OCA) under fasting conditions
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Generic obeticholic acid (OCA) under fed conditions
Number of subjects: 91

Group type: COMPARATOR
Intervention: Reference drug (OcalivaTM) under fasting conditions
Number of subjects: 91

Group type: COMPARATOR
Intervention: Reference drug (OcalivaTM) under fed conditions
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Food intake effect on pharmacokinetics
Number of subjects: 91
Study: 32938477

Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg/day for 7 days, then 400 mg/day for 7 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (equivalent number of placebo tablets for 14 days)
Number of subjects: 27
Study: 34255698

Group type: EXPERIMENTAL
Intervention: QuitPal-m app usage
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: QuitPal-m app usage with counselor advice
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Perceived app helpfulness
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Education level
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Perceived barriers to app use
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Phone technical problems
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Cigarettes smoked per day at end of treatment
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Counselor app advice
Number of subjects: 181
Study: 32468678

Group type: EXPERIMENTAL
Intervention: Not Scared of Sugar™ program
Number of subjects: 34
Study: 35851584

Group type: EXPERIMENTAL
Intervention: Sambucus williamsii var. coreana extract gargle
Number of subjects: 64

Group type: COMPARATOR
Intervention: Saline solution gargle
Number of subjects: 64
Study: 34325772

Group type: EXPERIMENTAL
Intervention: Tinidazole 200 mg/kg PO (single dose)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tinidazole 100 mg/kg PO (single dose)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tinidazole 20 mg/kg PO q12h (repeated dosing)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 21
Study: 36082667

Group type: EXPERIMENTAL
Intervention: CABG+CEA
Number of subjects: 127

Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 127
Study: 32347785

Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Number of subjects: 2146

Group type: COMPARATOR
Intervention: Licensed trivalent influenza vaccines (TIVs)
Number of subjects: 2146
Study: 35972777

Group type: EXPERIMENTAL
Intervention: RAW‐PA intervention (12-week intervention combining a wearable activity tracker with digital resources via a private Facebook group)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: RAW‐PA intervention
Number of subjects: 159

Group type: COMPARATOR
Intervention: wait-list control group
Number of subjects: 159
Study: 34488887

Group type: EXPERIMENTAL
Intervention: DDSS (Ada ? Your Health Guide)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: DDSS
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 102
Study: 34302544

Group type: EXPERIMENTAL
Intervention: Support-Based Spiritual Care Model nursing care
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study: 32372651

Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Number of subjects: 157

Group type: COMPARATOR
Intervention: Non-specific knee taping
Number of subjects: 157
Study: 35372380

Group type: EXPERIMENTAL
Intervention: Breathing-focused yoga intervention (BFY)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 140
Study: 34503795

Group type: EXPERIMENTAL
Intervention: Sauna group (SG)
Number of subjects: 36
Study: 36320178

Group type: EXPERIMENTAL
Intervention: Chlorhexidine vaginal cleansing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylactic antibiotics
Number of subjects: 0
Study: 34418588

Group type: EXPERIMENTAL
Intervention: 3D hologram learning module combined with classroom lectures
Number of subjects: 90

Group type: COMPARATOR
Intervention: Classroom lectures without 3D holograms
Number of subjects: 90
Study: 33203141

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (SAC/VAL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tocilizumab
Number of subjects: 0
Study: 35266155

Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 3115

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3115
Study: 34028457

Group type: EXPERIMENTAL
Intervention: Voice rehabilitation intervention group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group without rehabilitation
Number of subjects: 20
Study: 35930585

Group type: EXPERIMENTAL
Intervention: CT‐PLB combined with rapid on‐site evaluation (ROSE)
Number of subjects: 108

Group type: COMPARATOR
Intervention: No‐ROSE group
Number of subjects: 108
Study: 34037351

Group type: EXPERIMENTAL
Intervention: Ethylmethylhydroxypyridine succinate (Neurox) 1 tablet (125 mg) 3 times a day for 4 weeks
Number of subjects: 129

Group type: COMPARATOR
Intervention: Medical drugs (MD) not containing antihypoxants/antioxidants/nootropics
Number of subjects: 129
Study: 32478879

Group type: EXPERIMENTAL
Intervention: 3% microalgal product
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 3% niacinamide (vitamin B3)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Blue light irradiation (4 × 60 J cm−2, 450 nm)
Number of subjects: 33
Study: 35037963

Group type: EXPERIMENTAL
Intervention: HIVEC with 40 mg MMC (once weekly for 6 weeks, then once monthly for 6 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: BCG (once weekly for 6 weeks plus subsequent maintenance)
Number of subjects: 50
Study: 33726834

Group type: EXPERIMENTAL
Intervention: GSK2982772 60 mg orally 2 or 3 times daily for 84 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: GSK2982772 60 mg
Number of subjects: 52
Study: 32576791

Group type: EXPERIMENTAL
Intervention: Emergent endotracheal intubation (ETI)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Pre-intubation hypoxia (or an unobtainable pulse oximetry value) and younger than 1 year
Number of subjects: 543
Study: 33986049

Group type: EXPERIMENTAL
Intervention: 2 g carnosine for 15 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 15 weeks
Number of subjects: 50
Study: 32420695

Group type: EXPERIMENTAL
Intervention: ADSC‐CE topical solution applied twice daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 38
Study: 36449571

Group type: EXPERIMENTAL
Intervention: KETONE (0.29 g·kg‐1 of the ketone monoester (R)‐3‐hydroxybutyl (R)‐3‐hydroxybutyrate)
Number of subjects: 9

Group type: COMPARATOR
Intervention: CONTROL (no further nutrition provided)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: KETONE
Number of subjects: 9

Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 9
Study: 33394936

Group type: EXPERIMENTAL
Intervention: Clinically derived spectacle corrections
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Objective spectacle corrections derived from wavefront aberration data
Number of subjects: 30

Group type: COMPARATOR
Intervention: Habitual corrections
Number of subjects: 30
Study: 36194074

Group type: EXPERIMENTAL
Intervention: Smartphone app promoting Sharing, Mind, and Enjoyment (SME) behaviors, used daily over 1 month.
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Smartphone app promoting Sharing, Mind, and Enjoyment (SME) behaviors, used daily over 1 month (adherent subgroup).
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Smartphone app promoting Sharing, Mind, and Enjoyment (SME) behaviors.
Number of subjects: 390

Group type: COMPARATOR
Intervention: Waitlist control group (no app usage during the study period).
Number of subjects: 390
Study: 34261421

Group type: EXPERIMENTAL
Intervention: Uphill sprinting at steeper slopes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uphill sprinting at moderate slopes
Number of subjects: 0
Study: 35285853

Group type: EXPERIMENTAL
Intervention: Sotrovimab (500 mg intravenous infusion)
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1057
Study: 35696054

Group type: EXPERIMENTAL
Intervention: RIV‐TDS Test Product (transdermal patch formulation of Rivastigmine with a release rate of 13.3 mg/24 h)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Exelon Marketed Reference Product (transdermal patch formulation of Rivastigmine with a release rate of 13.3 mg/24 h)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: RIV‐TDS Test Product
Number of subjects: 31

Group type: COMPARATOR
Intervention: Exelon Marketed Reference Product
Number of subjects: 31
Study: 32573779

Group type: EXPERIMENTAL
Intervention: Long-term ADT (5 years)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Intermittent ADT
Number of subjects: 303
Study: 33300394

Group type: EXPERIMENTAL
Intervention: Cold-water immersion with higher CO2 concentration (CCWI)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cold tap-water immersion (CWI)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Passive recovery (PAS)
Number of subjects: 15
Study: 33600354

Group type: EXPERIMENTAL
Intervention: Tiger II catheter
Number of subjects: 180

Group type: COMPARATOR
Intervention: Judkins catheters (JR 4.0/JL 3.5)
Number of subjects: 180
Study: 32926604

Group type: EXPERIMENTAL
Intervention: Dasotraline (4, 6, or 8 mg/d)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Dasotraline
Number of subjects: 315
Study: 34878715

Group type: EXPERIMENTAL
Intervention: Standard-of-care (SOC) systemic therapy plus radical prostatectomy (RP) and pelvic lymphadenectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) systemic therapy
Number of subjects: 50
Study: 35485182

Group type: EXPERIMENTAL
Intervention: Test product (Haizheng Pharmaceutical Group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Reference drug (AstraZeneca Pharmaceuticals LP)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 46
Study: 33789567

Group type: EXPERIMENTAL
Intervention: Two-dimensional shear wave elastography (2D-SWE)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Indocyanine green (ICG) clearance test (ICG-R15)
Number of subjects: 215

Group type: COMPARATOR
Intervention: ALBI scores
Number of subjects: 215

Group type: COMPARATOR
Intervention: APRI
Number of subjects: 215

Group type: COMPARATOR
Intervention: FIB-4
Number of subjects: 215
Study: 36271849

Group type: EXPERIMENTAL
Intervention: RCF 75 mg once daily (QD)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: RCF 225 mg QD
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: RCF (both doses)
Number of subjects: 49
Study: 33435215

Group type: EXPERIMENTAL
Intervention: Tualang honey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gelam honey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kelulut honey
Number of subjects: 0
Study: 35613823

Group type: EXPERIMENTAL
Intervention: Dynamic bracing (Spinova Osteo orthosis) in addition to standard care
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard care (pain control with analgesics, physical therapy, and osteoporosis medication)
Number of subjects: 98
Study: 32427541

Group type: EXPERIMENTAL
Intervention: Instructor-provided graphic organizers (IP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Student-generated graphic organizers (SG)
Number of subjects: 60